Learn about

Our History

The History of Nortec Química

A general overview of the Company history

  • CREATION OF THE COMPANY

    On December 20, 1985, the NORQUISA group created the subsidiary NORTEC-NORDESTE QUÍMICA DESENVOLVIMENTOS TECNOLÓGICOS LTDA, embryo cell of NORTEC QUÍMICA S.A.

  • FIRST AGREEMENT WITH FIOCRUZ

    On January 17, 1986, the first amendment to the Technological Cooperation Agreement is signed between the Oswaldo Cruz Foundation (FIOCRUZ) and NORTEC-NORDESTE QUÍMICA DESENVOLVIMENTOS TECNOLÓGICOS LTDA.

  • NORTEC CHEMISTRY IS BORN

    NORDESTE QUÍMICA DESENVOLVIMENTOS TECNOLÓGICOS LTDA is going through a process of corporate reorganization. At that time, NORTEC QUÍMICA LTDA was born.
     
  • THE FIRST AWARD

    NORTEC QUÍMICA receives its first SINDUSFARMA (Pharmaceutical Industry Union) award, an award granted by the Pharmaceutical Industry to its best suppliers.

  • NORTEC QUÍMICA S.A

    The National Bank for Economic and Social Development (BNDES) joins the company and, at this moment, NORTEC QUÍMICA is transformed into a Public Limited Company, starting its expansion project, by building the third Chemical Synthesis unit. The Effluent Treatment Unit (UTE 500) is also inaugurated, designed by Coppe (Coordination of graduate studies in Engineering at UFRJ).
     
  • GROWTH OF THE COMPANY

    NORTEC QUÍMICA becomes the first company to be qualified with the PROFARMA PROGRAM designed to foster Research, Development and Technological Innovation programs - PROFARMA PD&I. This investment initiative was reflected in the expansion of NORTEC QUÍMICA's product portfolio, with the introduction of important Active Pharmaceutical Ingredients for the market, such as Benzodiazepines, Anti-Virals, Anti-retrovirals (anti-AIDS), Bronchodilators, Local Anesthetics and Drugs with action on the Central Nervous System.
     
  • THE IMPORTANCE OF NORTEC CHEMISTRY IN
    BRAZILIAN HEALTH

    In the Public-Private Partnerships (PPPs) model, NORTEC QUÍMICA is appointed by the Ministry of Health to participate in the following projects: TENOFOVIR DISOPROPXIL FUMARATE (anti-AIDS), MOFETILA MYCOPHENOLATE (drug against rejection in organ transplants), RALOXIFENO ( treatment of osteoporosis), RIVASTIGMINE (treatment of Alzheimer's disease).
     
  • A UNIQUE INDUSTRY

    NORTEC QUÍMICA starts the production of Benznidazole, IFA used in the treatment of Chagas Disease, being the only manufacturer of this medicine in the world.
     
  • THE FUTURE STARTS HERE

    NORTEC QUÍMICA starts the project to duplicate its U-200 unit, with investments in excess of R $ 50 million.
     
  • INTERNATIONAL RECOGNITION

    Em dezembro a empresa é auditada e aprovada pelo FDA (Food and Drug Administration) e ganha o Prêmio Kurt Politzer pelo projeto “Inovação na Fronteira do Conhecimento”, em parceria com o Instituto de Química da Universidade Federal do Rio de Janeiro (IQ-UFRJ). No mesmo ano é criada a Universidade Nortec.

  • PRODUCTIVE CAPACITY
    EXPANSION

    NORTEC QUÍMICA inaugurates two manufacturing units and completes the duplication of the effluent treatment station and the adjustments in the production areas, ending the project started in 2012.
     
  • A GREAT STEP

    NORTEC QUÍMICA signs a new contract with BNDES aiming at the expansion of laboratories and the production capacity with values exceeding R $ 30 million.